Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Higher-Risk Myelodysplastic Syndrome (HR-MDS)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07672769
What this trial is testing

Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

Who this might be right for
Higher Risk Myelodysplastic Syndromes
Faron Pharmaceuticals Ltd 90
Early research (Phase 1)Study completedNCT05564650
What this trial is testing

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromeRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome
Thomas Jefferson University 6
Early research (Phase 1)Looking for participantsNCT06994676
What this trial is testing

CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Who this might be right for
High-risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)AML - Acute Myeloid Leukemia+1 more
Crossbow Therapeutics, Inc. 72